Enovis (NYSE:ENOV) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Enovis (NYSE:ENOV) from a hold rating to a buy rating in a research note released on Saturday morning.

Several other equities analysts have also weighed in on the stock. UBS Group reissued a “buy” rating and issued a $50.00 price objective on shares of Enovis in a research report on Monday, January 5th. Canaccord Genuity Group reduced their target price on shares of Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a report on Wednesday, December 17th. Zacks Research upgraded shares of Enovis from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 4th. Evercore reissued an “outperform” rating on shares of Enovis in a report on Monday, January 12th. Finally, Needham & Company LLC raised their price objective on shares of Enovis from $49.00 to $52.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Enovis presently has a consensus rating of “Moderate Buy” and a consensus target price of $47.43.

Enovis Stock Performance

ENOV opened at $23.23 on Friday. The company has a quick ratio of 1.04, a current ratio of 2.02 and a debt-to-equity ratio of 0.85. Enovis has a 12-month low of $21.00 and a 12-month high of $40.69. The business has a 50 day moving average of $23.73 and a 200-day moving average of $27.72. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of -1.12 and a beta of 1.46.

Enovis (NYSE:ENOV) last posted its earnings results on Thursday, February 26th. The company reported $0.95 earnings per share for the quarter, topping analysts’ consensus estimates of $0.81 by $0.14. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.The business had revenue of $575.76 million for the quarter, compared to analyst estimates of $584.30 million. During the same period in the previous year, the firm earned $0.98 EPS. The firm’s revenue was up 2.6% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities research analysts expect that Enovis will post 2.79 earnings per share for the current year.

Insider Activity

In other Enovis news, insider Oliver Engert bought 1,000 shares of Enovis stock in a transaction dated Friday, February 27th. The stock was bought at an average price of $25.50 per share, with a total value of $25,500.00. Following the completion of the transaction, the insider owned 43,640 shares in the company, valued at $1,112,820. The trade was a 2.35% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have bought a total of 5,000 shares of company stock valued at $121,983 over the last three months. Insiders own 2.70% of the company’s stock.

Institutional Trading of Enovis

Several hedge funds and other institutional investors have recently bought and sold shares of ENOV. River Road Asset Management LLC boosted its holdings in Enovis by 3.2% in the 4th quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock valued at $39,621,000 after purchasing an additional 46,289 shares during the period. Corient Private Wealth LLC grew its position in shares of Enovis by 540.7% during the 4th quarter. Corient Private Wealth LLC now owns 55,180 shares of the company’s stock worth $1,470,000 after purchasing an additional 46,568 shares in the last quarter. Front Street Capital Management Inc. increased its holdings in shares of Enovis by 75.8% during the fourth quarter. Front Street Capital Management Inc. now owns 361,932 shares of the company’s stock worth $9,642,000 after purchasing an additional 156,069 shares during the period. XTX Topco Ltd acquired a new stake in shares of Enovis in the fourth quarter valued at approximately $561,000. Finally, Susquehanna Portfolio Strategies LLC raised its position in shares of Enovis by 249.9% in the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 140,997 shares of the company’s stock valued at $3,756,000 after buying an additional 100,704 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.